AstraZeneca PLC Voting Rights Report - March 2025 Insights

Here are the key points extracted from the financial report (Form 6-K) for AstraZeneca PLC:

1. Company Information:

• Name: AstraZeneca PLC
• Headquarters: 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom.

2. Report Date:

• The report is dated March 3, 2025, and pertains to the period ending February 28, 2025.

3. Total Voting Rights:

• The issued share capital of AstraZeneca PLC with voting rights is 1,550,607,175 ordinary shares of US$0.25 each.
• No shares are held in Treasury, thus the total number of voting rights is also 1,550,607,175.

4. Regulatory Compliance:

• This notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.
• The total number of voting rights can be used by shareholders to determine if they must notify their interest in AstraZeneca under the applicable rules.

5. Filing Details:

• The company files annual reports under Form 20-F and not under Form 40-F.
• The report indicates that the information is not being submitted to the Commission pursuant to Rule 12g3-2(b).

6. Company Overview:

• AstraZeneca is described as a global, science-led biopharmaceutical company focused on discovering, developing, and commercializing prescription medicines across various therapeutic areas, including oncology, rare diseases, and biopharmaceuticals.

7. Contact Information:

• The Company Secretary is Adrian Kemp, who is authorized to sign documents on behalf of AstraZeneca PLC.

This summary encapsulates the important details from the financial report, focusing on the total voting rights, regulatory compliance, and company information.